Search Contact
Learn more about our probiotics
with exclusive mechanisms of action

HERE
Discover our
clinical research

HERE
Neuropharmagen is a precision medicine
tool especially developed for psychiatry

MORE INFO
NEWS
Eighty-two percent of the shareholders from AB-Biotics approve of the exclusion of the company from the Alternative Stock Market
AB-Biotics celebrates at the Stock market of Barcelona an Extraordinary Shareholders Meeting which approved the proposal to exclude from the negotiation all of the company’s shares...
Read More
AB-Biotics presents biannual benefits for the first time
AB-Biotics has published the biannual accounts for the fiscal year 2019 where it has presented a positive result of 772,000 euros, against a loss of 377,000...
Read More
AB-Biotics proves the efficiency of the use of pharmacogenetics as a treatment of depression
AB-Biotics just published in the journal Pharmaceutics the results from a meta-analysis that prove the clinical utility of Neurofarmagen®, a pharmacogenetics tool, to select and guide the prescription of psychiatric drugs in adult patients with major depression, especially moderate-severe. For the development of this study, three clinical studies that were carried out in hospitals in Spain and South Korea were selected (with data from a total...
Read More
About ab-biotics
Research in its own
collection of more than
1.000 strains of
probiotic bacteria
Development of
advanced genetic tools
for pharmacogenetics
PROBIOTICS
Precision medicine